in a phase i/ii study the tolerable doses and antileukemic efficacy of the combination amsa and etoposide ( vp 16-213 ) was assessed in 20 patients with refractory acute myeloid leukemia .
C0015133
etoposide
C0023467
acute myeloid leukemia